FIELD: medicine; biotechnology.
SUBSTANCE: present invention relates to biotechnology and medicine, in particular to the use of phosphodiesterase 4D7 (PDE4D7) as a marker of hormone-resistant prostate cancer for distinguishing between hormone-sensitive and hormone-resistant cancer. Invention also relates to corresponding immunoassay, a method for identifying an individual suitable for therapy of hormone-resistant prostate cancer, and immunoassay for stratifying an individual or cohort of individuals with prostate cancer.
EFFECT: present invention can effectively diagnose hormone-resistant prostate cancer and distinguish between hormone-sensitive and hormone-resistant cancers.
11 cl, 12 dwg, 3 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHODIESTERASE 4D7 AS MARKER FOR AGGRESSIVE HORMONE-SENSITIVE PROSTATE CANCER | 2010 |
|
RU2575076C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| METHODS FOR PREDICTING PROSTATE CANCER | 2016 |
|
RU2760577C2 |
| PREOPERATIVE RISK STRATIFICATION BASED ON PDE4D7 AND DHX9 EXPRESSION | 2019 |
|
RU2793635C2 |
| ERYTHROFERRONE AND ERFE POLYPEPTIDES AND METHODS FOR REGULATING IRON METABOLISM | 2013 |
|
RU2684216C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| CANCER BIOMARKERS | 2007 |
|
RU2460075C2 |
| BIOMARKER | 2009 |
|
RU2573925C2 |
| DOUBLE TARGETING OF NUCLEOTIDE SEQUENCES MIR-208 AND MIR 499 IN TREATING CARDIAC DISEASES | 2010 |
|
RU2515926C2 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
